126799-85-7

Basic information

• Product Name: Benzene, 1-(azidomethyl)-3-chloro-
• CAS NO: 126799-85-7
• Molecular Formula: C7H6ClN3
• Molecular Weight: 167.598
• Mol File: 126799-85-7.mol
• Article Data: 57

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(azidomethyl)-3-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(azidomethyl)-3-chloro-(126799-85-7)
• EPA Substance Registry System: Benzene, 1-(azidomethyl)-3-chloro-(126799-85-7)

Safety Data

• Hazardous Substances Data: 126799-85-7(Hazardous Substances Data)

Upstream product

• 108-41-8 1-chloro-3-methylbenzene 
• 535-80-8 3-chlorobenzoate 
• 587-04-2 m-Chlorobenzaldehyde 
• 873-63-2 m-chlorobenzyl alcohol 
• 620-20-2 1-Chloro-3-chloromethyl-benzene 
• 1379314-35-8 C₈H₉ClO₃S 
• 766-80-3 1-bromomethyl-3-chlorobenzene 

Downstream Products

• 141072-01-7 di-tert-butyl 1-(3-chlorobenzyl)-1H-1,2,3-triazole-4,5-dicarboxylate 
• 1217341-91-7 C₁₅H₁₉ClN₆O₃S 
• 1245773-35-6 (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-(1-(3-chlorobenzyl)-1H-1,2,3-triazol-4-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate 
• 1256724-30-7 W(CO)5(C(OEt)C₂N₃(Ph)CH₂C₆H₄Cl) 
• 1370251-39-0 N-((1-(3-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-amine 
• 1376606-07-3 1-(3-chlorobenzyl)-4-hexyl-1H-1,2,3-triazole 
• 1376606-08-4 1-(3-chlorobenzyl)-4-decyl-1H-1,2,3-triazole 
• 1374838-95-5 1-(3-chlorobenzyl)-4-(p-tolyl)-1H-1,2,3-triazole 
• 1585234-65-6 (1-(3-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl 2-((5R,8S,8aS)-3,8-dimethyl-2-oxo-1,2,4,5,6,7,8,8a-octahydroazulen-5-yl)acrylate 
• 56620-45-2 1-chloro-3-(isocyanatomethyl)benzene 
• 126800-08-6 1‐(3‐chlorobenzyl)‐4‐phenyl‐1H‐1,2,3‐triazole 

Relevant articles and documents

Design and synthesis of new triazoles linked to xanthotoxin for potent and highly selective anti-gastric cancer agents

Two series of xanthotoxin-triazole derivatives were designed, synthesized, and studied for their antiproliferative properties. The in vitro cytotoxicity of the compounds in the AGS cancer cell line and the L02 normal cell line was evaluated via MTT assay. Among the synthesized compounds, 9-((1-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-7H-furo[3,2-g]chromen-7-one (6p) was found to have the greatest antiproliferative activity against AGS cells (IC50 = 7.5 μM) and showed better activity than the lead compound (xanthotoxin, IC50 > 100 μM) and the reference drug (5-fluorouracil, IC50 = 29.6 μM) did. The IC50 value of 6p in L02 cells was 13.3 times higher than that in the AGS cells. Therefore, the compound exhibited better therapeutic activity and specificity compared with the positive control 5-fluorouracil. Cell cycle analysis revealed that compound 6p inhibited cell growth via the induction of S/G2 phase arrest in AGS cells. Compound 6p was identified as a promising lead compound for the further development and identification of 1,2,3-triazole-based anticancer agents.

Synthesis, Docking, and Biological activities of novel Metacetamol embedded [1,2,3]-triazole derivatives

ERα controls the breast tissue development and progression of breast cancer. In our search for novel compounds to target Estrogen Receptor Alpha Ligand-Binding Domain, we identified “N-(3-((1H-1,2,3-triazol-4-yl)methoxy)phenyl)acetamide” derivatives as lead compounds. The Docking studies indicated good docking score for Metacetamol derivatives when docked into the 1XP6. A series of metacetamol derivatives have been synthesized, characterized and evaluated for cytotoxicity, anti bacterial and anti oxidant activities. Among the tested twelve hybrid compounds, “7a, 7g, 7h and 7i” derivatives showed promising cytotoxicity with IC50 value of 50 value of 30 μM, whereas Compounds “7a, 7b, 7c, 7d, 7g, 7j, 7k and 7l” showed moderate anti bacterial activity with the MIC value of 300 μM.

NOVEL DIBENZOOXAPHOSPHININE OXIDE DERIVATIVE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE DISEASE COMPRISING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel dibenzooxininin oxide derivative compound having various nitrogen-containing substituents introduced at 6-position of a dibenzooxaphosphorin oxide mononuclear, and to the use thereof. The present invention relates to a pharmaceutical composition for preventing or treating degenerative diseases and a health supplement food composition for preventing or treating degenerative diseases, comprising the dibenzooxaphosphorin oxide derivative compound of the present invention.